O6-Methylguanine DNA Methyltransferase (MGMT) Expression by Immunochemistry May Help Predict Response to Streptozotocin-based Chemotherapy in Pancreatic Neuroendocrine Tumours

#1546

Introduction: Streptozotocin (STZ) is an alkylating agent inducing DNA damage mainly repaired by MGMT. STZ-based chemotherapy is the first line treatment of non-resectable well-differentiated PNET. As for temozolomide, tumour MGMT deficiency may predict the efficacy of STZ in PNET.

Aim(s): Assessment of the predictive value of MGMT in a monocentric retrospective cohort of PNET treated with STZ-based chemotherapy.

Materials and methods: All patients with a well-differentiated PNET treated with a STZ-based chemotherapy according to the Moertel scheme between 01/2006 and 02/2014 were selected. Efficacy of the chemotherapy was assessed on CT-scan according to RECIST 1.1 and by PFS. MGMT expression was assessed by immunochemistry with a score (0-300) combining the % of positive cells by the intensity of the staining (0-3).

Conference: 13th Annual ENETSConcerence (2016)

Presenting Author: Hentic O

Authors: Hentic O, Cros J, Zappa M, Rebours V, Muller N,

Keywords: MGMT, Streptozotocin, PFS ,